Literature DB >> 18584988

An automated, high-throughput, 384 well Cytochrome P450 cocktail IC50 assay using a rapid resolution LC-MS/MS end-point.

Kuresh A Youdim1, Richard Lyons, Leon Payne, Barry C Jones, Kenneth Saunders.   

Abstract

The current study focused on the development of an automated IC50 cocktail assay in a miniaturized 384 well assay format. This was developed in combination with a significantly shorter high pressure liquid chromatography (HPLC) separation and liquid chromatography-mass spectrometry (LC-MS/MS) run-time; than those currently reported in the literature. The 384-well assay used human liver microsomes in conjunction with a cocktail of probe substrates metabolized by the five major CYPs (tacrine for CYP1A2, diclofenac for CYP2C9, (S)-mephenytoin for CYP2C19, dextromethorphan for CYP2D6 and midazolam for CYP3A4). To validate the usefulness of the automated and analytical methodologies, IC50 determinations were performed for a series of test compounds known to exhibit inhibition across these five major P450s. Eight compounds (sertraline, disulfuram, ticlopidine fluconazole, fluvoxamine, ketoconazole, miconazole, paroxetine, flunitrazepam) were studied as part of a cocktail assay, and against each CYPs individually. The data showed that the IC50s generated with cocktail incubations did not differ to a great extent from those obtained in the single probe experiments and hence unlikely to significantly influence the predicted clinical DDI risk. In addition the present method offered a significant advantage over some of the existing cocktail analytical methodology in that separation can be achieved with run times as short as 1 min without compromising data integrity. Although numerous studies have been reported to measure CYP inhibition in a cocktail format the need to support growing discovery libraries not only relies on higher throughput assays but quicker analytical run times. The current study reports a miniaturized high-throughput cocktail IC50 assay, in conjunction with a robust, rapid resolution LC-MS/MS end-point offered increased sample throughput without compromising analytical sensitivity or analyte resolution.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18584988     DOI: 10.1016/j.jpba.2008.05.011

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  14 in total

1.  Data Mining FAERS to Analyze Molecular Targets of Drugs Highly Associated with Stevens-Johnson Syndrome.

Authors:  Keith K Burkhart; Darrell Abernethy; David Jackson
Journal:  J Med Toxicol       Date:  2015-06

2.  Heterotropic activation of the midazolam hydroxylase activity of CYP3A by a positive allosteric modulator of mGlu5: in vitro to in vivo translation and potential impact on clinically relevant drug-drug interactions.

Authors:  Anna L Blobaum; Thomas M Bridges; Frank W Byers; Mark L Turlington; Margrith E Mattmann; Ryan D Morrison; Claire Mackie; Hilde Lavreysen; José M Bartolomé; Gregor J Macdonald; Thomas Steckler; Carrie K Jones; Colleen M Niswender; P Jeffrey Conn; Craig W Lindsley; Shaun R Stauffer; J Scott Daniels
Journal:  Drug Metab Dispos       Date:  2013-09-03       Impact factor: 3.922

3.  High-throughput fluorescence assay of cytochrome P450 3A4.

Authors:  Qian Cheng; Christal D Sohl; F Peter Guengerich
Journal:  Nat Protoc       Date:  2009-08-06       Impact factor: 13.491

4.  Discovery of VU0409106: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety.

Authors:  Andrew S Felts; Alice L Rodriguez; Ryan D Morrison; Daryl F Venable; Jason T Manka; Brittney S Bates; Anna L Blobaum; Frank W Byers; J Scott Daniels; Colleen M Niswender; Carrie K Jones; P Jeffrey Conn; Craig W Lindsley; Kyle A Emmitte
Journal:  Bioorg Med Chem Lett       Date:  2013-09-10       Impact factor: 2.823

5.  The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease.

Authors:  Carrie K Jones; Michael Bubser; Analisa D Thompson; Jonathan W Dickerson; Nathalie Turle-Lorenzo; Marianne Amalric; Anna L Blobaum; Thomas M Bridges; Ryan D Morrison; Satyawan Jadhav; Darren W Engers; Kimberly Italiano; Jacob Bode; J Scott Daniels; Craig W Lindsley; Corey R Hopkins; P Jeffrey Conn; Colleen M Niswender
Journal:  J Pharmacol Exp Ther       Date:  2011-11-16       Impact factor: 4.030

6.  Discovery of VU0431316: a negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety.

Authors:  Brittney S Bates; Alice L Rodriguez; Andrew S Felts; Ryan D Morrison; Daryl F Venable; Anna L Blobaum; Frank W Byers; Kera P Lawson; J Scott Daniels; Colleen M Niswender; Carrie K Jones; P Jeffrey Conn; Craig W Lindsley; Kyle A Emmitte
Journal:  Bioorg Med Chem Lett       Date:  2014-06-11       Impact factor: 2.823

7.  High-throughput fluorescence assay of cytochrome P450 3A4.

Authors:  Qian Cheng; F Peter Guengerich
Journal:  Methods Mol Biol       Date:  2013

8.  An improved substrate cocktail for assessing direct inhibition and time-dependent inhibition of multiple cytochrome P450s.

Authors:  Zhong-Hua Chen; Su-Xing Zhang; Na Long; Li-Shan Lin; Tao Chen; Fei-Peng Zhang; Xue-Qin Lv; Pei-Zhen Ye; Ning Li; Ke-Zhi Zhang
Journal:  Acta Pharmacol Sin       Date:  2016-04-11       Impact factor: 6.150

9.  Octahydropyrrolo[3,4-c]pyrrole negative allosteric modulators of mGlu1.

Authors:  Jason T Manka; Alice L Rodriguez; Ryan D Morrison; Daryl F Venable; Hyekyung P Cho; Anna L Blobaum; J Scott Daniels; Colleen M Niswender; P Jeffrey Conn; Craig W Lindsley; Kyle A Emmitte
Journal:  Bioorg Med Chem Lett       Date:  2013-07-23       Impact factor: 2.823

10.  Development of a fluorescence-based, ultra high-throughput screening platform for nanoliter-scale cytochrome p450 microarrays.

Authors:  Sumitra M Sukumaran; Benjamin Potsaid; Moo-Yeal Lee; Douglas S Clark; Jonathan S Dordick
Journal:  J Biomol Screen       Date:  2009-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.